iMMagine-6NCT07903506
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- New version filed on ClinicalTrials.gov
- Study First Submitted
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive high dose conditioning therapy with melphalan and autologous stem cell transplantation (auto-SCT). Following auto-SCT, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.
Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine for 3 days, followed by a single infusion of anitocabtagene autoleucel. Following anitocabtagene autoleucel, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.
Drugs: Anitocabtagene Autoleucel, Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, Fludarabine, Cyclophosphamide, Melphalan